Ask AI
ProCE Banner Activity

Optimizing DLBCL Treatment: An Expert Roundtable on the Role of New and Emerging Targeted Therapies

Slideset

Downloadable slides on the efficacy and safety of new and emerging targeted therapies in the management of patients with DLBCL.

Released: June 10, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with DLBCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues and patients on the mechanisms of action and rationales for using novel targeted therapies in DLBCL

  • Evaluate the potential clinical application of emerging evidence for novel targeted therapies in DLBCL

  • Recommend the optimal targeted treatment for each patient with DLBCL, considering subtype, comorbidities, expert recommendations, and available evidence

  • Identify patients with DLBCL who are eligible for clinical trials evaluating novel targeted therapies

Disclosure

Primary Author

Elizabeth Budde, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Crispr, Genentech/Roche; researcher: AstraZeneca, Merck.

Gilles Salles, MD, PhD: consultant/advisor/speaker: AbbVie, BeOne, Bristol Myers Squibb, Genentech/Roche, Genmab, Ipsen, Janssen, Kite/Gilead, Lilly, Merck, Novartis; independent contractor: AbbVie, Canopy, Daiichi Sankyo, Ellipses, Genentech/Roche, Genmab, Incyte, Kite/Gilead; researcher: AbbVie, Genentech, Genmab, Ipsen, Janssen.

Pier Luigi Zinzani, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Daichii Sankyo, Incyte, Janssen, Kite, Kyowa Kirin, Merck Sharp & Dohme, Novartis, Nurix, Roche, Sobi, Takeda.